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Summary
Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy 
versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate 
patterns of recurrence and did a post-hoc survival analysis.
Methods In the multicentre randomised phase 3 PORTEC-3 trial, women with high-risk endometrial cancer were 
eligible if they had International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I, endometrioid grade 
3 cancer with deep myometrial invasion or lymphovascular space invasion, or both; stage II or III disease; or stage I–III 
disease with serous or clear cell histology; were aged 18 years and older; and had a WHO performance status of 0–2. 
Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days 
per week) or chemoradiotherapy (two cycles of cisplatin 50 mg/m² given intravenously during radiotherapy, followed 
by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m² given intravenously), by use of a biased coin minimisation 
procedure with stratification for participating centre, lymphadenectomy, stage, and histological type. The co-primary 
endpoints were overall survival and failure-free survival. Secondary endpoints of vaginal, pelvic, and distant recurrence 
were analysed according to the first site of recurrence. Survival endpoints were analysed by intention-to-treat, and 
adjusted for stratification factors. Competing risk methods were used for failure-free survival and recurrence. We did 
a post-hoc analysis to analyse patterns of recurrence with 1 additional year of follow-up. The study was closed on 
Dec 20, 2013; follow-up is ongoing. This study is registered with ISRCTN, number ISRCTN14387080, and 
ClinicalTrials.gov, number NCT00411138.
Findings Between Nov 23, 2006, and Dec 20, 2013, 686 women were enrolled, of whom 660 were eligible and 
evaluable (330 in the chemoradiotherapy group, and 330 in the radiotherapy-alone group). At a median follow-up of 
72·6 months (IQR 59·9–85·6), 5-year overall survival was 81·4% (95% CI 77·2–85·8) with chemoradiotherapy 
versus 76·1% (71·6–80·9) with radiotherapy alone (adjusted hazard ratio [HR] 0·70 [95% CI 0·51–0·97], p=0·034), 
and 5-year failure-free survival was 76·5% (95% CI 71·5–80·7) versus 69·1% (63·8–73·8; HR 0·70 [0·52–0·94], 
p=0·016). Distant metastases were the first site of recurrence in most patients with a relapse, occurring in 78 of 
330 women (5-year probability 21·4%; 95% CI 17·3–26·3) in the chemoradiotherapy group versus 98 of 330 (5-year 
probability 29·1%; 24·4–34·3) in the radiotherapy-alone group (HR 0·74 [95% CI 0·55–0·99]; p=0·047). Isolated 
vaginal recurrence was the first site of recurrence in one patient (0·3%; 95% CI 0·0–2·1) in both groups (HR 0·99 
[95% CI 0·06–15·90]; p=0·99), and isolated pelvic recurrence was the first site of recurrence in three women (0·9% 
[95% CI 0·3–2·8]) in the chemoradiotherapy group versus four (0·9% [95% CI 0·3–2·8]) in the radiotherapy-alone 
group (HR 0·75 [95% CI 0·17–3·33]; p=0·71). At 5 years, only one grade 4 adverse event (ileus or obstruction) was 
reported (in the chemoradiotherapy group). At 5 years, reported grade 3 adverse events did not differ significantly 
between the two groups, occurring in 16 (8%) of 201 women in the chemoradiotherapy group versus ten (5%) of 
187 in the radiotherapy-alone group (p=0·24). The most common grade 3 adverse event was hypertension (in 
four [2%] women in both groups). At 5 years, grade 2 or worse adverse events were reported in 76 (38%) of 
201 women in the chemoradiotherapy group versus 43 (23%) of 187 in the radiotherapy-alone group (p=0·002). 
Sensory neuropathy persisted more often after chemoradiotherapy than after radiotherapy alone, with 5-year rates 
of grade 2 or worse neuropathy of 6% (13 of 201 women) versus 0% (0 of 187). No treatment-related deaths were 
reported.
Interpretation This updated analysis shows significantly improved overall survival and failure-free survival with 
chemoradiotherapy versus radiotherapy alone. This treatment schedule should be discussed and recommended, 
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Introduction
Women with endometrial cancer generally have a 
favourable prognosis;1 only about 15–20% have high-risk 
disease characteristics with an increased incidence of 
distant metastases and cancer-related death.2–4 High-risk 
endometrial cancer is defined as endometrioid 
endometrial cancer stage I, grade 3 with deep invasion, 
stage II or III endometrioid endometrial cancer (no 
residual disease), or non-endometrioid (serous or clear 
cell) histology.1
Women with high-risk endometrial cancer have been 
treated with pelvic external-beam radiotherapy for several 
decades. Findings of clinical trials comparing adjuvant 
chemotherapy alone with external-beam radiotherapy 
alone have shown no differ ences in survival outcomes.5,6 
Because a higher incidence of pelvic relapses has been 
reported with chemotherapy alone compared with a treat-
ment schedule including external-beam radiotherapy,7,8 
the combi nation of external-beam radiotherapy with 
chemo therapy has been explored in clinical trials.
especially for women with stage III or serous cancers, or both, as part of shared decision making between doctors and 
patients. Follow-up is ongoing to evaluate long-term survival.
Funding Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council, Project Grant, 
Cancer Australia Grant, Italian Medicines Agency, and the Canadian Cancer Society Research Institute.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Research in context
Evidence before this study
We searched PubMed for clinical studies published in English 
between Jan 1, 1980, and Dec 31, 2006, with the terms 
“endometrial cancer” AND “radiation therapy” AND 
“chemotherapy” AND “survival” OR “failure free survival” 
AND with the terms “endometrial cancer” AND “serous” 
AND “radiation therapy” AND “chemotherapy” AND “survival” 
OR “failure free survival”. Six relevant publications were 
identified. Among these, three randomised trials compared 
adjuvant chemotherapy with radiotherapy. No differences in 
overall and progression-free survival were found, whereas an 
increased frequency of pelvic relapse was reported after 
chemotherapy alone. Therefore, after these results, the next 
step was to explore the combination of concurrent 
chemotherapy and radiotherapy. Since the start of recruitment 
to the PORTEC-3 trial in 2006, the results of a pooled analysis of 
the NSGO-EC-9501/EORTC-55991 trial and the ManGO 
ILIADE-III trial were published, showing a significant 
improvement in progression-free survival and non-significant 
improvement in overall survival in women treated with four 
cycles of platinum-based chemotherapy given sequentially 
before or after pelvic radiotherapy versus those treated with 
radiotherapy alone. Results of two relevant trials (Gynecologic 
Oncology Group [GOG]-GOG 249 and GOG-258) have been 
published recently. The GOG-249 trial did not show improved 
progression-free survival with three cycles of 
carboplatin–paclitaxel with vaginal brachytherapy compared 
with pelvic radiotherapy in women with stage I–II disease with 
high (intermediate) risk factors. In the GOG-258 trial, women 
with stage III–IV endometrial cancer were randomly assigned to 
receive chemoradiotherapy (the same schedule as that used in 
the PORTEC-3 trial) or six cycles of carboplatin–paclitaxel alone. 
No differences in overall or recurrence-free survival were 
reported, but significantly more vaginal and pelvic or 
para-aortic recurrences were reported in the chemotherapy 
group than in the chemoradiotherapy group. The added value 
of chemotherapy to radiotherapy alone for women with serous 
cancer has, to our knowledge, been reported in retrospective 
series only. In a large retrospective study done in 135 women 
with stage I–IVA serous endometrial cancer, recurrence-free 
survival was improved by the combination of radiotherapy 
and chemotherapy. Subgroup analyses in randomised trials 
have not confirmed such benefits for serous cancers. 
The NSGO/EORTC trial reported improved progression-free 
survival with the addition of chemotherapy to radiotherapy for 
endometrioid cancers, but no such benefit was found for serous 
cancers.
Added value of this study
We report on the patterns of recurrence and provide updated 
survival outcomes of patients with high-risk endometrial cancer 
treated in the international randomised phase 3 PORTEC-3 trial. 
Patients were randomly assigned to receive pelvic radiotherapy 
alone or the combination of radiotherapy with concurrent 
(two cycles of cisplatin) and adjuvant (four cycles of 
carboplatin–paclitaxel) chemotherapy. Both overall and 
failure-free survival were significantly improved in women treated 
with combined adjuvant chemotherapy and radiotherapy 
compared with those treated with radiotherapy alone. In our 
post-hoc analysis of survival outcomes, the greatest absolute 
benefit was found for women with stage III or serous cancers, 
or both. In women with a recurrence, the majority had distant 
metastases. Pelvic control was excellent in both groups.
Implications of all the available evidence
Combined adjuvant chemotherapy and radiotherapy should be 
discussed and recommended as a new standard of care, 
especially for women with stage III endometrial cancer or serous 
cancers, or both. Shared decision making between doctors and 
their patients remains essential to weigh the costs and benefits 
for individual patients.
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The randomised phase 3 PORTEC-3 trial was initiated 
to investigate the benefit of a combined adjuvant 
chemotherapy and radiotherapy (chemoradiotherapy) 
schedule compared with external-beam radiotherapy 
alone for women with high-risk endometrial cancer. 
Previously reported efficacy results with a time-based 
analysis and a median follow-up of 60·2 months 
(IQR 48·1–73·1) showed a significant 7% improve-
ment in failure-free survival for patients treated with 
chemo radiotherapy compared with those treated with 
radio therapy alone (76% vs 69% at 5 years) without a 
significant difference in overall survival (82% vs 77% at 
5 years).9 In a subgroup analysis, the largest failure-free 
survival benefit with chemoradiotherapy (11%; 69% vs 
58% at 5 years) was observed in women with stage III 
disease, who have a higher baseline risk of recurrence 
than women with stage I–II disease.
The aim of the present analysis of the PORTEC-3 trial 
is to present the patterns of recurrence, treatment, and 
survival after recurrence and an updated (post-hoc) 
analysis of the primary endpoints with prolonged 
follow-up.
Methods
Study design and participants
PORTEC-3 was an open-label, multicentre, randomised 
intergroup phase 3 trial led by the Dutch Gynaecological 
Oncology Group (DGOG). The trial was done at 
103 centres (oncology centres, university hospitals, 
regional hospitals, or radiation oncology centres with 
referrals from regional hospitals) in six clinical trial 
groups collaborating in the Gynaecological Cancer 
Intergroup. Participating groups were the National 
Cancer Research Institute (NCRI; UK), the Australia and 
New Zealand Gynaecologic Oncology Group (ANZGOG; 
Australia and New Zealand), the Mario Negri Gynaecologic 
Oncology Group (MaNGO; Italy), the Canadian Cancer 
Trials Group (Canadian Cancer Trials Group; Canada), 
and Fedegyn (France).
Details about patient selection and treatment have 
been published previously.9,10 All patients first underwent 
surgery. In brief, surgery consisted of total abdominal 
or laparoscopic hysterectomy and bilateral salpingo-
oophorectomy. The extent of lymph node removal was 
left to the discretion of the participating centres, although 
pelvic lymph node debulking and para-aortic lymph node 
sampling were recommended in case of macroscopic 
positive pelvic nodes or para-aortic nodes, or both. Full 
surgical staging (including omentectomy, peritoneal 
biopsies, and lymph node sampling) was recommended 
for patients with serous or clear cell cancer. FIGO 2009 
staging was assigned on the basis of surgical and 
pathological findings. Central pathology review was 
mandatory before randomisation to confirm eligibility 
for study entry.11
Eligible patients were women with histologically 
confirmed endometrioid endometrial cancer with either 
International Federation of Gynecology and Obstetrics 
(FIGO) 2009 stage IA grade 3 with documented 
lymphovascular space invasion; stage IB grade 3 disease; 
stage II disease; stage IIIA, IIIB (parametrial invasion), 
or IIIC disease; or stage IA–III with serous or clear cell 
histology (IA with invasion). Eligibility criteria also 
included WHO performance score 0–2; adequate bone 
marrow function (white blood cell count ≥3·0 × 10⁹ cells 
per L, platelets ≥100 × 10⁹ per L), liver function (bilirubin 
≤1·5 × upper limit of normal, aspartate aminotransferase 
to alanine aminotransferase ratio ≤2·5 × upper limit of 
normal) and kidney function (creatinine clearance 
>60 mL/min calculated according to Cockroft and Gault 
or >50 mL/min edetic acid [EDTA] clearance), and age 
18 years or older (without an upper age limit, because 
elderly women might benefit from the study treatment 
if they were deemed fit enough to undergo chemo-
therapy). Exclusion criteria were uterine sarcoma or 
carcino sarcoma, previous malignancy (except for non-
melanomatous skin cancer) within the past 10 years, 
previous pelvic radiotherapy, previous hormonal therapy 
or chemotherapy, bulky cervical involvement with radical 
hysterectomy, inflammatory bowel disease, residual 
macro scopic tumour, impaired renal or cardiac function, 
neuropathy grade 2 or worse, hearing impairment 
grade 3 or worse, or a congenital hearing disorder.
Written informed consent was obtained from all 
patients. The protocol was approved by the Dutch Cancer 
Society and by the ethics committees of all participating 
groups. The study protocol is available online.
Randomisation and masking
Patients were randomly assigned (1:1) to open-label 
treatment groups with chemoradiotherapy or radio-
therapy alone, by use of a biased-coin minimisation 
procedure ensuring balance overall and within each 
stratum of the stratification factors (participating centre, 
lymphadenectomy [yes vs no], FIGO 2009 stage of cancer 
[IA vs IB vs II vs III]), and histological type [endometrioid 
carcinoma vs serous or clear cell carcinoma]). Patients 
were registered and randomly assigned by the data 
centres of the participating groups and treatment was 
assigned with a web-based application. Participants, 
physicians, and investigators were not masked to 
treatment allocation.
Procedures
External-beam pelvic radiotherapy was given to patients 
in both treatment groups to a total dose of 48·6 Gy in 
1·8 Gy fractions, 5 days per week. Specifications of 
the treatment schedule have been reported previously.9–11 
In case of glandular or stromal cervical involvement, 
or both, a brachytherapy boost was given. Brachytherapy 
dose was equivalent to 14 Gy in 2 Gy fractions (with 
a recommended scheme of 10 Gy high-dose rate in 
fractions of 5 Gy). Treatment was recommended to start 
within 4–6 weeks of surgery, but no later than 8 weeks 
For the study protocol see 
http://www.msbi.nl/portec3
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after surgery. Overall radiotherapy treatment time was 
not to exceed 50 days.
In the chemoradiotherapy group, women received 
two cycles of cisplatin 50 mg/m² administered intra-
venously in the first and fourth week of external-beam 
radiotherapy, followed by four cycles of carboplatin AUC5 
and paclitaxel 175 mg/m² administered intravenously at 
21-day intervals. This schedule was based on the 
RTOG-9708 trial,12 with substitution of cisplatin by 
carboplatin in the adjuvant phase. Adjuvant chemo-
therapy was started within 3 weeks after completion of 
external-beam pelvic radiotherapy, and with a 28-day 
interval from the second concurrent cycle. Cisplatin was 
postponed for 1 week in the event of haematological, 
renal, or other toxicities or discontinued if recovery 
required more than 1 week or in the case of grade 2 
or worse neuropathy. Carboplatin was postponed or 
stopped in case of severe haematological toxicity. 
Paclitaxel was postponed if grade 2 neuropathy developed 
and stopped if recovery exceeded 1 week or if grade 3 
neuropathy developed. Details about chemotherapy 
stopping rules have been described previously.10
Follow-up was focused on patient history and pelvic 
examination to detect adverse events (grade ≥2 
according to Common Terminology Criteria for Adverse 
Events [CTCAE] version 3.0) and symptoms of recurrent 
disease, with annual chest radiographs, blood counts, 
and chemistry tests (including CA-125) until 5 years 
after randomisation. Long-term follow-up of vital status 
and events was required at 7 years and 10 years. Health-
related quality-of-life assessments were done at 
baseline, at the end of radiotherapy, at 6-month intervals 
from randomisation until 24 months, and at 36 and 
60 months.
Patients who immediately withdrew informed consent 
after randomisation without any information were 
excluded from the analysis, as were patients who 
were ineligible for the study. There were no other criteria 
for a patient to be removed from the study.
Outcomes
The co-primary endpoints were overall survival and 
failure-free survival. Overall survival was defined as the 
time from randomisation to death from any cause. 
Failure-free survival was defined as the time 
from randomisation to any relapse, or death related 
to endometrial cancer or treatment, whichever occurred 
first. Women who were alive were censored at the date of 
their last follow-up. Secondary endpoints were vaginal, 
pelvic, or distant recurrence; treatment-related toxicity; 
and health-related quality of life.10 Recurrences were 
analysed according to first site of recurrence as well as 
the total number of recurrences. Simultaneous vaginal 
and pelvic recurrence was considered pelvic recurrence; 
and simultaneous vaginal, pelvic, and distant recur-
rence was considered distant recurrence. Abdominal 
recurrences outside the pelvic area (peritoneal carci-
nomatosis, liver, and para-aortic lymph nodal metastases) 
were considered distant metastases, with specification of 
site. After diagnosis of any relapse, treatment infor-
mation was required and follow-up continued according 
to protocol guidelines. An extensive update on quality of 
life will be reported separately in a future publication.
Statistical analysis
The PORTEC-3 trial was powered (80%) to detect a 
10% difference in 5-year overall survival between the 
treatment groups (increase from 65% to 75%; hazard 
ratio [HR] 0·67), with a two-sided test at an α level of 
0·05. 198 overall survival events were required, with a 
minimum of 655 patients. A prespecified interim 
analysis was done in September, 2013, after 48 overall 
survival events (a third of the required events) had 
occurred. The final analysis of the co-primary endpoints 
was published in February, 2018, with permission of the 
data and safety monitoring board as a time-based analysis 
rather than an event-based analysis since a median 
follow-up of 60·2 months had been reached and because 
the event rate was lower than expected.
To maintain an overall α of 0·05 with a nominal 
α level for the interim analysis of 0·0002, the final 
analysis was done with a nominal α of 0·0498. The 
final time-based analysis was done with a corre-
lation of 0·7859 between the test statistics of the co-
primary endpoints overall survival and failure-free 
survival (based on 136 overall survival events and 
186 failure-free survival events), and a nominal α 
of 0·0309 was used for each of the analyses, resulting 
in an overall α level of 0·0498.13 The sequential rejection 
principle14 implies that if the null hypothesis of no 
treatment difference for one of the co-primary 
endpoints is rejected (p<0·0309), the null hypothesis of 
no treatment difference for the other co-primary 
endpoint can then be assessed at the 0·05 level, while 
still retaining a family-wise error rate of 0·05.
The current analysis was done to evaluate patterns of 
recurrences, together with a non-prespecified post-hoc Figure 1: Trial profile
343 assigned to radiotherapy
330 received treatment and included in 
 intention-to-treat population
 328 received allocated treatment
 2 received chemoradiotherapy
13 excluded
 4 immediately withdrew 
  informed consent
 9 not eligible
343 assigned to chemoradiotherapy
330 received treatment and included in 
 intention-to-treat population
 325 received allocated treatment
 5 received radiotherapy only
13 excluded
 9 immediately withdrew 
  informed consent
 4 not eligible
686 patients enrolled and randomly assigned
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analysis of survival after recurrence as well as an 
updated analysis of overall survival and failure-free 
survival with prolonged follow-up and 5-year adverse 
events. Final database lock was on Nov 29, 2018.
We did statistical analyses using SPSS, 
version 23.0.0.2, and R, version 3.5.1. All analyses were 
done by intention to treat, excluding ineligible patients 
and those who immediately withdrew informed consent 
after randomi sation. Differences in relapse and survival 
rates between the groups were tested with the log-rank 
test and Cox regression analysis. The analysis of the 
primary endpoints was adjusted for the stratification 
factors (participating group, lymphaden ectomy, stage of 
cancer, and histological type), since a stratified 
minimisation procedure was used at randomi sation.15,16 
For the adjusted analysis, stratification factors were 
included as covariates in the Cox model. The 
proportional hazards assumption for treatment was 
checked by use of Schoenfeld residuals for overall 
survival and failure-free survival, and was not found to 
be violated.17 Patient characteristics were compared 
with a χ² test. Survival after recurrence was compared 
with a log-rank test and for this analysis 
the first site of recurrence was used. Competing risk 
Chemoradiotherapy 
group (n=330)
Radiotherapy alone 
group (n=330)
Any recurrence 
(n=185)
No recurrence 
(n=475)
p value*
Age at randomisation, years
Median (IQR) 62·4 (56·5–67·9) 62·0 (55·8–68·2) 63·9 (59·0–69·9) 60·9 (55·5–67·6) ..
Age group <0·0001
<60 years 128 (39%) 140 (42%) 54 (29%) 214 (45%) ··
60–69 years 144 (44%) 128 (39%) 86 (47%) 186 (39%) ··
≥70 years 58 (18%) 62 (19%) 45 (24%) 75 (16%) ··
FIGO 2009 stage <0·0001
Stage IA 39 (12%) 39 (12%) 14 (8%) 64 (14%) ··
Stage IB 59 (18%) 58 (18%) 22 (12%) 95 (20%) ··
Stage II 80 (24%) 90 (27%) 42 (23%) 128 (27%) ··
Stage IIIA 46 (14%) 37 (11%) 22 (12%) 61 (13%) ··
Stage IIIB 18 (6%) 24 (7%) 19 (10%) 23 (5%) ··
Stage IIIC 88 (27%) 82 (25%) 66 (36%) 104 (22%) ··
Histological grade and type <0·0001
Endometrioid endometrial carcinoma† grade 1–2 127 (39%) 131 (40%) 61 (33%) 197 (42%) ··
Endometrioid endometrial carcinoma† grade 3 107 (32%) 106 (32%) 59 (32%) 154 (32%) ··
Serous cancer 53 (16%) 52 (16%) 47 (25%) 58 (12%) ··
Clear cell cancer 29 (9%) 33 (10%) 17 (9%) 45 (10%) ··
Other 14 (4%) 8 (2%) 1 (1%) 21 (4%) ··
Myometrial invasion 0·010
<50% 116 (35%) 123 (37%) 53 (29%) 186 (39%) ··
≥50% 212 (65%) 206 (63%) 132 (71%) 286 (61%) ··
Missing 2 1 0 3 ··
Lymphovascular space invasion 0·008
Present 197 (60%) 192 (58%) 124 (67%) 265 (56%) ··
Absent 133 (40%) 138 (42%) 61 (33%) 210 (44%) ··
WHO performance status score 0·70
0–1 323 (98%) 324 (98%) 181 (98%) 466 (99%) ··
≥2 5 (2%) 5 (2%) 4 (2%) 6 (1%) ··
Missing 2 1 0 3 ··
Type of surgery
TAH and BSO 97 (29%) 97 (29%) 58 (31%) 136 (29%) 0·866
TAH and BSO plus LND or full staging 141 (43%) 132 (40%) 72 (39%) 201 (42%) ··
TLH and BSO 45 (14%) 42 (13%) 25 (14%) 62 (13%) ··
TLH and BSO plus LND or full staging 47 (14%) 59 (18%) 30 (16%) 76 (16%) ··
Data are n (%) or median (IQR), unless otherwise stated. FIGO=International Federation of Gynaecology and Obstetrics. TAH=total abdominal hysterectomy. BSO=bilateral 
salpingo-oopherectomy. LND=lymph node dissection. TLH=total laparoscopic hysterectomy. Missing values are not taken into account for the percentages. *χ² test of 
variables between patients with versus without any recurrence. †Endometrioid endometrial carcinoma including mixed tumours with less than 25% of serous or clear cell 
component.
Table 1: Baseline characteristics, by treatment group and by recurrence status
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methods were used for analysis of failure-free survival 
and recurrence, by calculating cumulative incidences 
and Fine-Gray regression.18 For failure-free survival, 
inter current death was used as a competing risk. 
For the first failure analysis of recurrences, all other 
recurrences and death were used as competing risks. 
Median survival after recurrence was calculated as the 
first timepoint at which the Kaplan-Meier curve was 
below 50% survival. The IQR was calculated similarly. 
In the multivariable analysis, the following covariates 
were included together with treatment: stage, 
histological type and grade, type of surgery, participating 
groups, lymphovascular space invasion, and age. The 
median follow-up and IQR was estimated with the 
reverse Kaplan-Meier method.
This study is registered with ISRCTN, number 
ISRCTN14387080, and ClinicalTrials.gov, number 
NCT00411138.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data interpretation, data analysis, 
or writing of this report. The central data manager 
(KWV), the chief investigator (CLC), the associated 
investigators (SMdB and RAN), and the trial statistician 
(HP) had full access to all the data. The decision to 
submit for publication was made after discussion within 
the trial management group. The corresponding 
author and chief investigator had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Nov 23, 2006, and Dec 20, 2013, 686 women 
were enrolled and randomly assigned to chemoradio-
therapy (n=343) or radiotherapy (n=343); 26 patients 
were excluded after randomisation (figure 1), resulting 
in 660 patients in the intention-to-treat analysis 
(330 in each group). Median follow-up was 72·6 months 
(IQR 59·9–85·6) at the time of the current analysis 
and 75% of participants had reached at least 5 years of 
follow-up.
Patient characteristics were well balanced between the 
treatment groups (table 1). The median age of the 
enrolled patients was 62 years (IQR 56–68). Baseline 
characteristics of patients with and without a recurrence 
are given in table 1.
Radiotherapy was completed in 329 (>99%) of 
330 women in the chemoradiotherapy group and in 
325 (99%) of 330 in the radiotherapy alone group. Vaginal 
brachytherapy was given to 309 (47%) of 660 patients: 
151 (46%) of 330 patients on chemoradiotherapy and 
158 (48%) of 330 on radiotherapy alone. In the chemo-
radiotherapy group, concurrent cis platin was completed 
by 304 (92%) of 330 women, adjuvant carboplatin by 
262 (79%), and adjuvant paclitaxel by 233 (71%). At least 
one dose reduction of cisplatin (to 40 mg/m²) was 
recorded for five (2%) patients, of carboplatin (from 
AUC5 to AUC4) for 36 (11%) patients, and of paclitaxel 
(from 175 mg/m² to 135 mg/m²) for 50 (15%) patients. 
Chemotherapy was discontinued in 61 (18%) of 
330 patients: because of toxicity in 31 (9%), the patient’s 
decision in 20 (6%), disease progression in seven (2%), 
and for other reasons in three (1%).9,10
At the final database lock (Nov 29, 2018), 150 patients 
had died (65 in the chemoradiotherapy group and 85 in 
the radiotherapy alone group) and 189 patients had a 
failure-free survival event (84 in the chemoradiotherapy 
group and 105 in the radiotherapy alone group). This 
number of events comprised 76% (150 of 198) of required 
overall survival events and 95% (189 of 198) of failure-free 
survival events for the final analysis. Most deaths were 
Figure 2: Kaplan-Meier survival curves for overall survival (A) and failure-free survival (B) in all patients
HR=hazard ratio.
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related to endometrial cancer: 53 (82%) of 65 in the 
chemoradiotherapy group versus 76 (89%) of 85 in 
the radiotherapy group. Among women assigned to 
chemoradiotherapy, other causes of death were second 
cancers (in five [8%] patients), other intercurrent disease 
(in three [5%] patients), and complications of treatment 
for metastatic disease (in two [3%] patients). Among 
women assigned to radiotherapy alone, other causes of 
death were second cancers (in five [6%] patients), 
other intercurrent disease (in one [1%] patient), and 
complications of treatment for metastatic disease (in 
one [1%] patient). The cause of death was uncertain 
for two patients treated with chemoradiotherapy and 
two patients treated with radiotherapy alone; these deaths 
were considered failure-free survival events since a 
relation to endometrial cancer or to treatment for 
endometrial cancer could not be excluded.9
Estimated 5-year overall survival adjusted for 
stratification factors was 81·4% (95% CI 77·2–85·8) 
with chemoradiotherapy versus 76·1% (71·6–80·9) with 
radiotherapy alone (HR 0·70 [95% CI 0·51–0·97], 
p=0·034). Estimated 5-year failure-free survival adjusted 
for stratification factors was 76·5% (95% CI 71·5–80·7) 
with chemoradiotherapy versus 69·1% (63·8–73·8) with 
radiotherapy alone (HR 0·70 [95% CI 0·52–0·94], 
p=0·016; figure 2).
In our post-hoc exploratory analysis of survival 
outcomes by disease stage, women with stage III 
disease had significantly lower overall survival and 
failure-free survival than women with stage I–II 
disease, irrespective of treatment received (appendix 
p 6). In women with stage III endometrial cancer, 
5-year overall survival was 78·5% (95% CI 72·2–85·4) 
with chemoradiotherapy versus 68·5% (61·2–76·7) 
with radiotherapy alone (HR 0·63 [95% CI 0·41–0·99]; 
p=0·043), and 5-year failure-free survival was 70·9% 
(95% CI 62·9–77·4) with chemo radiotherapy versus 
58·4% (49·8–66·0) with radiotherapy alone (HR 0·61 
[95% CI 0·42–0·89]; p=0·011; figure 3A, B). In women 
with stage I–II disease, 5-year overall survival was 
83·8% (95% CI 78·4–89·5) with chemoradiotherapy 
versus 82·0% (95% CI 76·5–87·7) with radiotherapy 
alone HR 0·84 [95% CI 0·52–1·38]; p=0·50), and 5-year 
failure-free survival was 81·3% (95% CI 74·7–86·3) 
with chemoradiotherapy versus 77·3% (95% CI 
70·5–82·7) with radiotherapy alone (HR 0·87 [95% CI 
0·56–1·36]; p=0·54; appendix p 8).
When comparing serous cancers with all other 
histologies in a post-hoc exploratory subgroup analysis, 
women with serous cancers had significantly lower 
overall survival and failure-free survival than did those 
Figure 3: Kaplan-Meier survival curves for overall survival (A) and failure-free 
survival (B) among patients with stage III endometrial cancer, and overall 
survival (C) and failure-free survival (D) for patients with serous cancer
HR=hazard ratio.
0 1 2 3 4 5 6 7
143 (0) 137 (1) 123 (1) 109 (1) 99 (5) 78 (21) 55 (42) 28 (68)
152 (0) 145 (0) 133 (1) 119 (4) 117 (6) 93 (27) 65 (52) 43 (73)
0 1 2 3 4 5 6 7
143 (0) 116 (1) 95 (1) 85 (2) 78 (7) 63 (21) 48 (35) 26 (56)
152 (0) 139 (0) 122 (0) 111 (4) 105 (6) 81 (27) 55 (50) 35 (69)
0 1 2 3 4 5 6 7
52 (0) 47 (0) 43 (0) 33 (1) 27 (3) 21 (7) 18 (9) 12 (15)
53 (0) 48 (0) 41 (1) 39 (1) 33 (5) 26 (12) 14 (23) 9 (27)
Time since randomisation (years)
0 1 2 3 4 5 6 7
52 (0) 38 (0) 31 (0) 24 (2) 21 (4) 17 (8) 14 (10) 10 (14)
53 (0) 48 (0) 36 (0) 34 (0) 30 (4) 22 (10) 13 (19) 9 (23)
A   Overall survival in stage III
O
ve
ra
ll 
su
rv
iv
al
 (%
)
100
80
60
20
40
0
Number at risk
(number censored)
Radiotherapy
Chemoradiotherapy
B   Failure-free survival in stage III
Fa
ilu
re
-f
re
e 
su
rv
iv
al
 (%
)
100
80
60
20
40
0
Number at risk
(number censored)
Radiotherapy
Chemoradiotherapy
C   Overall survival for serous cancers
O
ve
ra
ll 
su
rv
iv
al
 (%
)
100
80
60
20
40
0
Number at risk
(number censored)
Radiotherapy
Chemoradiotherapy
D   Failure-free survival for serous cancers
Fa
ilu
re
-f
re
e 
su
rv
iv
al
 (%
)
100
80
60
20
40
0
Number at risk
(number censored)
Radiotherapy
Chemoradiotherapy
Radiotherapy
Chemoradiotherapy
5-year overall survival: 78·5% (chemoradiotherapy) vs 68·5% (radiotherapy)
HR 0·63 (95% CI 0·41–0·99); pcoxadjusted=0·043
5-year failure-free survival: 70·9% (chemoradiotherapy) vs 58·4% (radiotherapy)
HR 0·61 (95% CI 0·42–0·89); pcoxadjusted=0·011
5-year overall survival: 71·4% (chemoradiotherapy) vs 52·8% (radiotherapy)
HR 0·48 (95% CI 0·24–0·96); pcoxadjusted=0·037
5-year failure-free survival: 59·7% (chemoradiotherapy) vs 47·9% (radiotherapy)
HR 0·42 (95% CI 0·22–0·80); pcoxadjusted=0·008
Articles
1280 www.thelancet.com/oncology   Vol 20   September 2019
with other histologies irrespective of treatment received 
(appendix p 7), and the difference in overall survival and 
failure-free survival among the different disease stages 
was more pronounced for serous cancers than for other 
histologies (appendix pp 10, 11). After adjusting for 
stratification factors, significant improvements in over-
all survival and failure-free survival were observed for 
serous cancers treated with chemoradiotherapy versus 
radiotherapy alone: 5-year overall survival was 71·4% 
(95% CI 60·1–84·7) with chemoradiotherapy versus 
52·8% (40·6–68·6) with radiotherapy alone (HR 0·48 
[95% CI 0·24–0·96]; p=0·037), and 5-year failure-free 
survival was 59·7% (95% CI 45·1–71·6) with chemo-
therapy versus 47·9% (33·9–60·6) with radiotherapy 
alone (HR 0·42 [95% CI 0·22–0·80]; p=0·008; 
figure 3C, 3D).
Stage, histological type and grade, type of surgery, 
participating groups, lymphovascular space invasion, 
and age were included in the prespecified multivariable 
analysis for overall and failure-free survival. Compared 
with radiotherapy alone, chemoradiotherapy significantly 
improved overall and failure-free survival in the presence 
of these factors (appendix p 5). Most factors, except for 
lymphadenectomy (and lymphovascular space invasion 
for overall survival) were correlated with overall survival 
and failure- free survival (appendix p 5). In a post-hoc 
analysis of survival outcomes by type of surgery, the type 
of surgery (laparotomy vs laparoscopy) did not affect 
overall survival or failure-free survival (appendix p 13).
Distant metastases were the first type of recurrence in 
most patients with a recurrence, and occurred in 98 of 
330 patients (5-year probability 29·1% [95% CI 24·4–34·3] 
in the radiotherapy-only group compared with 78 of 
330 patients (5-year probability 21·4% [17·3–26·3] in the 
chemoradiotherapy group (HR 0·74 [95% CI 0·55–0·99]; 
p=0·047; table 2). In the radiotherapy group, 74 (76%) of 
these 98 recurrences were distant recurrence only (of 
which 12 were isolated para-aortic nodal recurrences); 
20 patients had combined distant and pelvic recurrences 
(including two with distant, pelvic, and vaginal 
recurrences), and four had combined distant and vaginal 
recurrences. In the chemoradiotherapy group, 63 (81%) 
of 78 distant recurrences were distant only (of which nine 
were isolated para-aortic nodal recurrences); 11 were 
combined distant and pelvic recurrences (including one 
with distant, pelvic, and vaginal recurrence), and four 
were combined distant and vaginal recurrences.
Isolated vaginal recurrence was the first site of 
recurrence in one patient (0·3% [95% CI 0·0–2·1]) in 
both groups (HR 0·99 [95% CI 0·06–15·90]; p=0·99), 
and isolated pelvic recurrence was the first site of 
recurrence in four women (0·9% [0·3–2·8]) in the 
radiotherapy group and in three (0·9% [0·3–2·8]) in 
the chemoradiotherapy group (HR 0·75 [95% CI 
0·17–3·33]; p=0·71; table 2).
Figure 4 shows recurrences by cancer stage and 
histological type. Recurrences were highest in women 
with stage IIIB (19 [45·2%] of 42) and stage IIIC 
(66 [38·8%] of 170) disease. Across the different 
histological types, the greatest risk of recurrence was 
for serous cancers (47 [44·8%] of 105), followed by clear 
cell cancers (17 [27·4%] of 62) and grade 3 endometrioid 
endometrial cancer (59 [27·7%] of 213).
Median survival after recurrence was 1·4 years 
(IQR 0·5–3·7) in the total PORTEC-3 cohort and did not 
differ significantly between the two treatment groups: 
1·4 years (0·7–3·7) for patients in the radiotherapy group 
and 1·2 years (0·4–8·9) in the chemoradiotherapy group 
(HR 1·06 [95% CI 0·75–1·51]; p=0·72; table 3). In both 
groups, about 9–10% of patients (n=33; 16 in the 
radiotherapy group and 17 in the chemoradiotherapy 
group) survived for several years after recurrence 
(appendix p 12). In these cases, recurrences were more 
often solitary metastases and low grade in type, and more 
often treated with hormonal therapy (data not shown).
In terms of treatment after recurrence, patients in the 
radiotherapy group were more likely to be treated with 
chemotherapy for their first recurrence than those in the 
chemoradiotherapy group (48 [47%] of 103 women vs 
30 [37%] of 82 women), and most women in the 
radiotherapy group (43 [90%] of 48) received carboplatin 
plus paclitaxel (details of treatment received by the other 
five women are provided in the appendix (p 3). In the 
chemoradiotherapy group, various combinations of 
chemotherapy agents were used (data not shown) and 
only 12 (40%) of 30 patients received carboplatin plus 
paclitaxel again (details of treatment received by the other 
18 women are provided in the appendix p 3). An overview 
Number of 
events
5-year probability 
(95% CI)
Hazard ratio 
(95% CI)
Log-rank 
p value*
Vaginal recurrence (first recurrence)
Chemoradiotherapy 1 0·3% (0·0–2·1) 0·99 (0·06–15·90) 0·99
Radiotherapy alone 1 0·3% (0·0–2·1) ·· ··
Pelvic recurrence (first recurrence)
Chemoradiotherapy 3 0·9% (0·3–2·8) 0·75 (0·17–3·33) 0·71
Radiotherapy alone 4 0·9% (0·3–2·8) ·· ··
Distant metastases (first recurrence)
Chemoradiotherapy 78 21·4% (17·3–26·3) 0·74 (0·55–0·99) 0·047
Radiotherapy alone 98 29·1% (24·4–34·3) ·· ··
Vaginal recurrence (total)
Chemoradiotherapy 8 2·1% (1·0–4·4) 0·99 (0·37–2·65) 0·99
Radiotherapy alone 8 2·1% (1·0–4·4) ·· ··
Pelvic recurrence (total)
Chemoradiotherapy 20 5·5% (3·5–8·6) 0·63 (0·36–1·11) 0·11
Radiotherapy alone 31 8·5% (5·9–12·1) ·· ··
Distant metastases (total)
Chemoradiotherapy 80 22·1% (17·9–27·0) 0·75 (0·56–1·01) 0·057
Radiotherapy alone 99 29·4% (24·7–34·6) ·· ··
*Unadjusted for stratification factors.
Table 2: Recurrence outcomes by treatment group
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of all treatment modalities is given in the appendix 
(pp 3, 14).
A comprehensive overview of adverse events during 
treatment and the first few years after treatment has 
been provided in previous publi cations.9,10 After longer 
follow-up, we found no significant differences between 
the two treatment groups in grade 3 or worse adverse 
events at 12, 36, and 60 months after randomisation 
(appendix p 4). 60 months after randomisation, grade 3 
adverse events were reported for 16 (8%) of 201 women 
in the chemoradiotherapy group versus ten (5%) of 
187 women in the radiotherapy group (p=0·24). Only one 
grade 4 adverse event (ileus or obstruction) was reported 
(in the chemoradio therapy group). The most frequently 
reported grade 3 adverse events were hypertension (in 
four women [2%] in both groups), any pain (in three [1%] 
women in the chemoradiotherapy group vs three [2%] in 
the radio therapy group) and other toxicities (in three [1%] 
women in the chemoradiotherapy group vs two [1%] in 
the radiotherapy group).
At 60 months, grade 2 or worse adverse events were 
reported for 76 (38%) of 201 women in the chemo-
radiotherapy group versus 43 (23%) of 187 women in 
the radiotherapy group (p=0·002). Sensory neuropathy 
grade 2 or worse was the major difference between the 
two groups at 5 years, seen in 13 (6%) of 201 patients after 
chemoradiotherapy versus no patients in the radiotherapy 
group (table 4).
Discussion
These updated results of the PORTEC-3 trial, with a 
longer median follow-up of 72 months and with 75% of 
participants having reached 5 years of follow-up, showed 
a significant improvement in both overall and failure-
free survival with chemoradiotherapy versus radio-
therapy alone for high-risk endometrial cancer. The 
absolute improvement at 5 years was 5% (HR 0·70; 95% 
CI 0·51–0·97) for overall survival and 7% (0·70; 
0·52–0·94) for failure-free survival. Most recurrences 
were at distant sites, with excellent local and regional 
control in both groups. Women in the radiotherapy 
group were more likely to receive chemo therapy for their 
first recurrence. Women with serous cancers had worse 
overall survival and failure-free survival than those with 
other histological types, and for these women a 
significant improvement of overall survival (absolute 
improvement 19%; HR 0·48 [95% CI 0·24–0·96]) and 
failure-free survival (absolute improvement 12%; 0·42 
[0·22–0·80]) was found with chemoradiotherapy 
compared with radiotherapy alone.
External-beam radiotherapy has been the standard 
adjuvant treatment for women with high-risk endo-
metrial cancer for several decades. Since trials com-
paring adjuvant chemotherapy alone with external-beam 
radiotherapy alone did not show differences in survival,5,6 
the combination of external-beam radiotherapy with four 
cycles of platinum-based chemotherapy was investigated 
in the randomised NSGO-EC-9501/EORTC-55991 trial.19 
A pooled analysis with the ManGO ILIADE-III trial 
showed a significant improvement in progression-free 
survival at 5 years with chemoradiotherapy versus 
radiotherapy alone (78% vs 69%, p=0·01) and a non-
significant improvement in 5-year overall survival (82% 
vs 75%; p=0·07).19 The RTOG 9708 phase 2 trial 
investigated combined external-beam radiotherapy with 
concurrent and adjuvant chemotherapy, with both 
treatment modalities started early after surgery. This 
combination showed manageable toxicity and a 5-year 
overall survival of 85% and relapse-free survival of 79%. 
The PORTEC-3 trial confirmed these high survival rates 
in a large randomised trial, with estimated 5-year overall 
Figure 4: Recurrences divided by stage (A) and histology (B)
FIGO=International Federation of Gynaecology and Obstetrics.
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survival of 79% and 5-year failure-free survival of 73% in 
the chemoradiotherapy group.
High-risk endometrial cancer comprises a hetero-
geneous group of tumours with both early-stage disease 
with high-risk features and advanced stage endometrial 
cancer and non-endometrioid tumours. When analysing 
results by stage, women with stage III endometrial 
cancer had a significantly higher risk of recurrence than 
did those with stage I–II disease. For women with 
stage I–II endometrial cancer, combined adjuvant 
treatment yielded only a small absolute improvement of 
2% (HR 0·84; 95% CI 0·52–1·38) in 5-year overall 
survival and of 4% (0·87; 0·56–1·36) in failure-free 
survival. These results are supported by the results of 
the Gynecologic Oncology Group (GOG)-249 trial, in 
which women with stage I–II endometrial cancer were 
randomly assigned to receive external-beam radio therapy 
or vaginal brachy therapy and three cycles of carboplatin–
paclitaxel chemo therapy. No differences in overall 
survival or recurrence-free survival were reported, but 
pelvic and para-aortic recurrences were significantly 
more frequent after vaginal brachytherapy and 
chemotherapy.20 Taking the results of the GOG-249 and 
PORTEC-3 trials together, a minimal benefit in failure-
free survival and overall survival in stage I–II endometrial 
cancer achieved with chemo radiotherapy does not seem 
to justify the increased frequency of adverse events, 
impaired quality of life, and longer treatment duration of 
combined treatment for these patients.
For women with stage III endometrial cancer in 
PORTEC-3, a significant improvement in overall survival 
(HR 0·63) and in failure-free survival (HR 0·61) was 
found with chemoradiotherapy versus radiotherapy alone. 
In the GOG-258 trial, 813 women with stage III–IVA 
endometrial cancer were randomly assigned to receive 
pelvic external-beam radiotherapy with concurrent and 
adjuvant chemotherapy (with the same schedule as that of 
the PORTEC-3 trial), or to receive chemotherapy alone 
(six cycles of carboplatin and paclitaxel).21 Although 
no differences in recurrence-free and overall survival were 
found, significantly more vaginal recurrences (HR 0·36) 
and pelvic or para-aortic, or both, recurrences (HR 0·43) 
were seen in women treated with chemotherapy alone. 
While using the same chemoradiotherapy schedule as in 
PORTEC-3, recurrence-free survival in GOG-258 was 
59% (97% stage III) compared with 71% in PORTEC-3 
for stage III disease. In retrospective cohorts, a high 
frequency of locoregional recurrence was also found 
after treatment with chemotherapy alone,7,8,22 supporting 
the continued use of pelvic radiotherapy in patients 
undergoing adjuvant chemotherapy. Taking the findings 
of these two recent large trials together, the addition of 
chemotherapy should be discussed and recommended 
for women with stage III endometrial cancer to improve 
failure-free and overall survival as part of shared decision 
making between doctors and their patients.
Overall and failure-free survival for women with serous 
cancers were lower than for those with endometrioid and 
clear cell cancers, and the difference in overall survival 
and failure-free survival among the different disease 
stages was more pronounced for women with serous 
cancers than for those with other histologies. Retro-
spective studies have reported improvements in overall 
survival and recurrence-free survival with chemotherapy 
for serous cancers.23,24 In several randomised trials, 
however, subgroup analyses for treatment effect in 
different histological types did not confirm such 
benefits.19,20,25 In a GOG study of four randomised 
chemotherapy trials in women with meta static and 
recurrent endometrial cancer, comprising 1203 patients, 
no association was found between response and 
histological type.26 In the PORTEC-3 trial, however, a 
significant improvement in both overall survival and 
failure-free survival was found for women with serous 
cancers treated with chemoradiotherapy. However, such 
subgroup analyses should be interpreted with caution 
for several reasons. The number of patients with serous 
cancer in these trials is relatively small, and serous 
cancers have often been grouped together with clear cell 
cancers. In the current PORTEC-3 analysis, we found 
that the frequency of recurrence among women with 
clear cell cancers was similar to that of women with 
endometrioid tumours and clearly lower than that of 
women with serous cancers. Another factor to consider 
when interpreting subgroup analyses is the use of 
different chemotherapy regimens among the different 
trials. In the NSGO/EORTC trial,19 the GOG-122 trial,25 
and the GOG metastatic endometrial cancer analysis,26 
cisplatin-based combinations were used, whereas in the 
PORTEC-3, GOG-249, and GOG-258 trials, carboplatin 
and paclitaxel were given.
Number 
of 
events
Median 
survival,* 
years (IQR)
Hazard 
ratio 
(95% CI)
Log-rank 
p value†
Vaginal or pelvic recurrence
Chemoradiotherapy 4 1·2 (0·7–NR) ·· ··
Radiotherapy alone 6 1·4 (0·9–NR) ·· ··
Total 10 1·4 (0·9–NR) 1·31 
(0·26–6·55)
0·74
Distant metastases
Chemoradiotherapy 76 1·2 (0·3–8·9) ·· ··
Radiotherapy alone 93 1·5 (0·7–3·7) ·· ··
Total 169 1·4 (0·5–3·7) 1·05 
(0·73–1·50)
0·79
Any recurrence
Chemoradiotherapy 82 1·2 (0·4–8·9) ·· ··
Radiotherapy alone 103 1·4 (0·7–3·7) ·· ··
Total 185 1·4 (0·5–3·7) 1·06 
(0·75–1·51)
0·72
NR=not reached. *For median survival after recurrence, the first site of recurrence 
was used. †Unadjusted for stratification factors.
Table 3: Median survival after recurrence
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In the PORTEC-3 trial, 105 patients with serous cancers 
were included. PORTEC-3 is the first randomised trial 
to show a significant improvement in overall survival 
and failure-free survival with combined adjuvant 
treatment for women with serous cancers, but in absolute 
terms mostly for higher stage disease. The number of 
women and events are too low to report on treatment 
efficacy across the different stages of serous cancers. 
To achieve further improvements in survival outcomes 
for women with serous cancers, targeted therapies based 
on molecular alterations should be explored. Serous 
cancers are characterised by a high frequency of TP53 
mutations, and in approximately 25% of patients an 
overexpression of HER2/neu has been reported, with a 
potential progression-free survival benefit by addition of 
trastuzumab to chemotherapy.27,28
Most first recurrences in the PORTEC-3 trial were at 
distant sites, with only few simultaneous vaginal or pelvic 
recurrences. Isolated vaginal or pelvic recurrence was 
rare. This finding is in line with other randomised trials 
that used radiotherapy in both groups.19,20 In the 
PORTEC-3 schedule, which was based on the RTOG-9708 
phase 2 trial,12 both treatment modalities were started 
early after surgery, aiming at achieving rapid efficacy of 
both treatment modalities and potential increase of the 
effect of radiotherapy by the two concurrent cycles. This 
schedule has now been proven safe and effective in 
two large, randomised trials with toxicity and quality-
of-life data, whereas no phase 3 evidence is available 
for the specific benefit for other sequences of radio-
therapy and chemotherapy.9,10,19,21 Widespread differences 
exist in the practice of giving chemotherapy and 
Grade 2 Grade 3*
Chemoradiotherapy 
group (n=201)
Radiotherapy alone 
group (n=187)
p value† Chemoradiotherapy 
group (n=201)
Radiotherapy alone 
group (n=187)
p value‡
Any 59 (29%) 33 (18%) 0·002 16 (8%) 10 (5%) 0·24
Allergic reaction or hypersensitivity 0 0 0·48 0 1 (1%) 0·48
Auditory or hearing 4 (2%) 1 (1%) 0·29 2 (1%) 1 (1%) 1·00
Hypertension 16 (8%) 16 (9%) 0·87 4 (2%) 4 (2%) 1·00
Lymphatics (oedema) 5 (2%) 0 0·06 0 0 1·00
Gastrointestinal (any) 16 (8%) 9 (5%) 0·19 2 (1%) 1 (1%) 1·00
Constipation 3 (1%) 1 (1%) 1·00 0 1 (1%) 1·00
Diarrhoea 7 (3%) 7 (4%) 1·00 0 0 1·00
Ileus or obstruction 2 (1%) 1 (1%) 0·37 2 (1%) 0 0·50
Haematological (any) 5 (2%) 5 (3%) 1·00 0 0 1·00
Lymphocytes 3 (1%) 4 (2%) 0·74 0 0 1·00
Infection (without neutropenia) 2 (1%) 0 0·12 2 (1%) 0 0·50
Neuropathy (any) 13 (6%) 0 <0·0001 1 (<1%) 0 1·01
Motor neuropathy 1 (<1%) 0 0·50 1 (<1%) 0 1·02
Sensory neuropathy 12 (6%) 0 <0·0001 1 (<1%) 0 1·03
Neurology (other) 1 (<1%) 0 0·25 2 (1%) 0 0·50
Pain (any) 13 (6%) 5 (3%) 0·15 3 (1%) 3 (2%) 1·00
Joint pain 7 (3%) 2 (1%) 0·14 2 (1%) 1 (1%) 1·00
Muscle pain 1 (<1%) 1 (1%) 0·61 0 1 (1%) 0·48
Back/pelvic/limbs 0 2 (1%) 0·11 0 1 (1%) 0·48
Abdomen/cramps 2 (1%) 0 0·12 2 (1%) 0 0·50
Other 2 (1%) 1 (1%) 1·00 1 (<1%) 1 (1%) 1·00
Musculoskeletal (other) 0 1 (1%) 1·00 1 (<1%) 0 1·00
Genitourinary ·· ·· ·· ·· ·· ··
Incontinence 8 (4%) 9 (5%) 1·00 0 0 1·00
Urinary frequency 8 (4%) 2 (1%) 0·14 0 1 (1%) 0·48
Constitutional ·· ·· ·· ·· ·· ··
Fatigue 0 3 (2%) 0·11 0 0 1·00
Other 0 0 1·00 1 (<1%) 0 1·00
Other toxicity 4 (2%) 4 (2%) 1·00 3 (1%) 2 (1%) 1·00
Data are n (%). *Only one grade 4 adverse event was reported 60 months after randomisation for a women treated in the chemoradiotherapy group (ileus or obstruction). 
†Significance level: p<0·01 for grade ≥2 events. ‡Significance level: p<0·01 for grade ≥3 events. The prevalence of toxicity graded according to the Common Terminology 
Criteria for Adverse Events version 3.0 was calculated at each timepoint. For each adverse event, the maximum grade per patient was recorded (worst ever by patient).
Table 4: Grade 2 and 3 adverse events reported at 60 months after randomisation
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radiotherapy in either sequence or in a so-called sandwich 
schedule; concurrent start of both modalities might be 
most effective and efficient. Since most first recurrences 
were at distant sites (although with fewer in the combined 
treatment group than in the radiotherapy-only group), 
one could speculate whether multi-agent chemotherapy 
should already be given concurrently. However, no 
evidence exists for other concurrent schedules in 
endometrial cancer, whereas, for example, weekly 
carboplatin and paclitaxel has been shown to be effective 
in patients with oesophageal cancer.
In a patient preference study done by the ANZGOG 
group among their PORTEC-3 participants,29 more than 
50% of women reported a 5% survival improvement or an 
extra 1 year survival as being sufficient to make chemo-
therapy worthwhile. Although both co-primary endpoints 
showed a significant improvement and are within this 
range, weighing the benefits of chemoradiotherapy 
against the increased risk of adverse events remains 
important. Significantly more severe adverse events and 
reduced health-related quality of life were reported in the 
combined treatment group during the first year after 
treatment.9,10 However, rapid recovery was seen, with no 
significant differences in grade 3–4 adverse events from 
12 months onwards. At 60 months after randomisation, 
significantly more patients reported grade 2 toxicity with 
the combination treatment, of which sensory neuropathy 
is the most significant (6% vs 0%) and clinically 
relevant.9,10
A limitation of this analysis is that the subgroup 
analyses were not powered and the survival update was a 
non-prespecified, post-hoc analysis, with an additional 
follow-up time of 12 months after 95% of the required 
failure-free survival events had occurred. However, 
the previous (time-based) analysis already showed a 
significant improvement in failure-free survival, and the 
overall survival difference was close to significance. 
The differences in overall and failure-free survival have 
remained and have even become stronger with a longer 
follow-up time and more events recorded.
In terms of the statistical significance of our findings, 
the p value for failure-free survival was 0·016 and that 
for overall survival was 0·034, whereas the boundary 
for claiming positivity of the study based on Pocock 
correction was 0·031 (ie, if either or both of the p values 
were lower than 0·031 the study is deemed positive). The 
sequential rejection principle14 implies that, since the null 
hypothesis of no treatment difference for failure-free 
survival was rejected (p<0·031), the null hypothesis of no 
treatment difference for the co-primary endpoint of 
overall survival can then be assessed at the 0·05 level, 
while still retaining a family-wise error rate of 0·05. 
Application of this principle implies that the treatment 
effect for overall survival can be considered significant.
Better selection of women for adjuvant treatment 
might be achieved by integration of molecular char-
acteristics. For intermediate-risk endo metrial cancer, 
an improved risk assessment was reported with an 
integrated profile of clinicopathological and molecular 
risk factors.30 This approach is currently being tested in 
the randomised PORTEC-4a trial (NCT03469674). A pilot 
study of the TransPORTEC consortium showed that 
determination of the molecular subgroups as described 
by the Cancer Genome Atlas Group27 also improved risk 
assessment in high-risk endometrial cancer. Translational 
research is being done on tumour tissue samples donated 
by PORTEC-3 participants as part of an international 
collaboration. The molecular subgroups and additional 
molecular characteristics will be ascertained and the 
benefit of adjuvant chemotherapy in relation to these 
factors will be explored.
In conclusion, this updated analysis of the PORTEC-3 
trial shows improved 5-year overall and failure-free 
survival with chemoradiotherapy compared with radio-
therapy alone for women with high-risk endometrial 
cancer, with the greatest absolute benefit for chemo-
therapy seen in women with stage III disease or serous 
cancers, or both. Most recurrences were at distant sites, 
suggesting that new systemic treatment approaches are 
needed to improve survival outcomes. Molecular analysis 
has the potential to improve risk stratification and should 
be used to identify subgroups that can derive the greatest 
benefit from chemotherapy and to select patients for 
targeted therapies; molecular studies on tissue samples 
donated by PORTEC-3 trial participants are ongoing.
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